

Jennifer June Brown et

Serial No. 10/042,711

Filed: December 12, 2001

Page 3 (AMENDMENT IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-
PROVISIONAL APPLICATION – COMPLIANCE WITH REQUIREMENTS OF 37 CFR 1.821-1.825
SEQUENCE RULES –
December 30, 2002)

REMARKS

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto; and applicants hereby petition for any needed extension of time...

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,


Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

Dated: December 30, 2002

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100

Amendment.re.sequence.rules.123002.Enz57(CIP)(C)


ENZ-57(CIP)(C)

Jennifer June Brown et

Serial No. 10/042,711

Filed: December 12, 2001

Page 4 (AMENDMENT IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-
PROVISIONAL APPLICATION – COMPLIANCE WITH REQUIREMENTS OF 37 CFR 1.821-1.825
– SEQUENCE RULES –
December 30, 2002)



MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 10/042,711

Marked up version of the paragraph starting at page 11, lines 19-25, is below:

In situ PCR amplification and detection of HBV RNA. Reactions were carried out according to the protocol described in Liu et al., (1997; J. Vir. 71:4079) except that HBV specific sequences for primers and probe were used. The sequences for these is as follows:

HBV A: 5'-TGCCTGAGTGC(TA)GTATG-3' (SEQ ID NO: 1)

HBV B: 5'-TAGGAGGCTGTAGGCAT-3' (SEQ ID NO: 2)

HB Probe: 5'-TTTATAAGGGTCGATGTCCAT-3' (SEQ ID NO: 3)

ENZ-57(CIP)(C)